U.S. markets close in 4 hours 36 minutes
  • S&P 500

    4,204.03
    +81.56 (+1.98%)
     
  • Dow 30

    33,329.91
    +555.50 (+1.69%)
     
  • Nasdaq

    12,810.80
    +316.87 (+2.54%)
     
  • Russell 2000

    1,962.58
    +49.69 (+2.60%)
     
  • Crude Oil

    89.12
    -1.38 (-1.52%)
     
  • Gold

    1,814.80
    +2.50 (+0.14%)
     
  • Silver

    20.74
    +0.26 (+1.26%)
     
  • EUR/USD

    1.0353
    +0.0135 (+1.33%)
     
  • 10-Yr Bond

    2.7430
    -0.0540 (-1.93%)
     
  • GBP/USD

    1.2254
    +0.0177 (+1.47%)
     
  • USD/JPY

    132.3900
    -2.7260 (-2.02%)
     
  • BTC-USD

    23,976.18
    +828.58 (+3.58%)
     
  • CMC Crypto 200

    564.42
    +33.20 (+6.25%)
     
  • FTSE 100

    7,503.38
    +15.23 (+0.20%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate.

  • "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement.

  • The bivalent vaccine targets the beta variant and the original strain of the virus.

  • Related: Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern.

  • In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID and 72% against infections specifically caused by the omicron variant.

  • When used in people who previously had COVID, the results were stronger. The vaccine generated an efficacy rate of 75.1% against symptomatic COVID and 93.2% in omicron-confirmed symptomatic cases.

  • The new data supporting the bivalent vaccine will be submitted to regulatory authorities.

  • Sanofi and GSK's original COVID-19 vaccine is already under review by the European Medicines Agency.

  • Price Action: SNY shares are up 3.27% at $52.07, and GSK stock is up 1.01% at $43.18 during the premarket session on the last check Friday.

  • Photo by Gerd Altmann from Pixabay

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.